Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

1.330 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acrivon Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Acrivon Posts Narrower Loss in Q2
Via The Motley Fool
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
From Acrivon Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Top stock movements in today's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Tuesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
On Wednesday, there are stocks with unusual volume. Let's take a look.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
These stocks have an unusual volume in today's session
Volume analysis on 2025-04-01: stocks with an unusual volume in today's session. 
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
From Acrivon Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings
 
Via Benzinga
Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion
 
Via Benzinga
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.